Jun. 9 at 1:37 AM
$ELOX ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of
$11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of
$10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the
$0.01 per share exercise price of each pre-funded warrant. All of the securities to be sold in the offering are being offered by Eloxx. Eloxx expects to receive gross proceeds of
$66.0 million, before deducting underwriting discounts
